Semaglutide Linked to 50-56% Lower Risk of Alcohol Use Disorder in Large Real-World Study
In a real-world study of 83,825 obesity patients and 598,803 T2D patients, semaglutide was associated with 50-56% lower risk for both new and recurring alcohol use disorder compared to other anti-obesity medications, consistent across gender, age, and race.
Quick Facts
What This Study Found
Semaglutide was associated with 50-56% lower risk for both incidence and recurrence of alcohol use disorder compared to other anti-obesity medications, consistent across demographic subgroups and replicated in a T2D cohort.
Key Numbers
83,825 patients with obesity; 50-56% lower risk for both incidence and recurrence of alcohol use disorders; compared to other anti-obesity medications.
How They Did This
Retrospective cohort study using electronic health records. Primary cohort: 83,825 obesity patients. Replication cohort: 598,803 T2D patients. Compared semaglutide vs. other anti-obesity medications. Outcomes: AUD incidence and recurrence over 12-month follow-up. Stratified by gender, age, race, and diabetes status.
Why This Research Matters
Alcohol use disorder is a top-10 global cause of disease burden with limited effective treatments. If semaglutide genuinely reduces alcohol use, it could fill an enormous therapeutic gap — especially since it's already widely prescribed for diabetes and obesity, meaning the safety profile is well-established and access infrastructure exists.
The Bigger Picture
Semaglutide's potential effects on addictive behaviors represent one of the most surprising developments in GLP-1 agonist research. GLP-1 receptors are expressed in brain reward circuits, and preclinical studies show GLP-1 agonists reduce alcohol intake in animals. This large real-world study adds substantial human evidence that the brain-reward effects are clinically meaningful. Combined with similar findings for tobacco, this suggests GLP-1 agonists may broadly modulate addictive behaviors.
What This Study Doesn't Tell Us
Retrospective observational study — cannot prove causation. Potential confounders include differences in health-seeking behavior between semaglutide and comparator users. AUD diagnosis depends on clinical recognition, which may be inconsistent. No data on actual alcohol consumption amounts. Medication adherence not assessed. Self-reported desire to drink was not measured.
Questions This Raises
- ?Does semaglutide reduce actual alcohol consumption, or does it just reduce the likelihood of being diagnosed with AUD?
- ?What is the mechanism — does GLP-1 receptor activation in brain reward circuits reduce the reinforcing effects of alcohol?
- ?Would semaglutide be effective as a primary treatment for AUD in patients without obesity or diabetes?
Trust & Context
- Key Stat:
- 50-56% lower AUD risk for both incidence and recurrence, vs. other anti-obesity medications, consistent across gender, age, race, and diabetes status in 83,825 obesity patients + 598,803 T2D patients
- Evidence Grade:
- Moderate — large retrospective cohort study with replication in an independent cohort. Strong associations but observational design cannot establish causation. Randomized trials needed for definitive evidence.
- Study Age:
- Published in 2024, among the first large-scale real-world evidence studies examining semaglutide's association with alcohol use disorder.
- Original Title:
- Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
- Published In:
- Nature communications, 15(1), 4548 (2024)
- Authors:
- Wang, William(3), Volkow, Nora D(3), Berger, Nathan A(2), Davis, Pamela B, Kaelber, David C, Xu, Rong
- Database ID:
- RPEP-09493
Evidence Hierarchy
Frequently Asked Questions
Could semaglutide help people quit drinking?
This large study found people taking semaglutide were 50-56% less likely to develop or relapse into alcohol use disorder compared to those on other medications. However, this was an observational study — not a clinical trial — so we can't be certain semaglutide caused the reduction. The effect may relate to GLP-1 receptors in brain reward circuits that also govern alcohol cravings. Clinical trials specifically testing semaglutide for alcohol use disorder are needed.
Should people take semaglutide to reduce drinking?
No — semaglutide is currently approved only for type 2 diabetes and obesity, not for alcohol use disorder. While the real-world evidence is promising, prescribing semaglutide specifically for AUD would be premature. If you're concerned about alcohol use, speak with your doctor about approved treatments. If you're already taking semaglutide and notice reduced desire to drink, that's consistent with what this research suggests.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09493APA
Wang, William; Volkow, Nora D; Berger, Nathan A; Davis, Pamela B; Kaelber, David C; Xu, Rong. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.. Nature communications, 15(1), 4548. https://doi.org/10.1038/s41467-024-48780-6
MLA
Wang, William, et al. "Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.." Nature communications, 2024. https://doi.org/10.1038/s41467-024-48780-6
RethinkPeptides
RethinkPeptides Research Database. "Associations of semaglutide with incidence and recurrence of..." RPEP-09493. Retrieved from https://rethinkpeptides.com/research/wang-2024-associations-of-semaglutide-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.